HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma.

Abstract
The aim of the present investigation was to formulate a docetaxel (DTX) and gemcitabine (GEM) co-loaded PEGylated liposome (DTX/GEM-L) to increase the therapeutic efficacy in osteosarcoma (OS). 2-Hydroxypropyl-γ-cyclodextrin/DTX inclusion complex was made to increase DTX aqueous solubility. DTX/GEM-L was characterized for morphological shape and size parameters. Release study showed a sustained release pattern for both the drugs. The nanocarriers based combinational drug significantly increased the cytotoxic effect than the free drug combination at the same concentration. The cell cycle analysis showed a predominant G2/M phase arrest for combinational drug. Importantly, more than 20% of cells were in late apoptosis chamber for DTX/GEM-L treatment with significant proportion of cells in the early apoptosis and necrotic phases. The antitumor efficacy was tested in MG63 cancer cell bearing xenograft nude mice. Results showed that DTX/GEM-L significantly reduced the tumor burden comparing to that of free combination cocktail. The PEGylated liposome successfully delivered the anticancer drugs in the osteosarcoma tumor interstitial spaces via EPR effect. DTX/GEM-L showed excellent safety profile along with the remarkable tumor suppression ability. Overall, results suggest that nanocarriers-based delivery system remarkably enhanced the apoptosis and cytotoxicity and increased the potency of combinational drug regimen.
AuthorsLiang Sun, Dong-Sheng Zhou, Peng Zhang, Qing-Hu Li, Ping Liu
JournalInternational journal of pharmaceutics (Int J Pharm) Vol. 478 Issue 1 Pg. 308-317 (Jan 15 2015) ISSN: 1873-3476 [Electronic] Netherlands
PMID25433201 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Retracted Publication)
CopyrightCopyright © 2014. Published by Elsevier B.V.
Chemical References
  • Antineoplastic Agents
  • Delayed-Action Preparations
  • Drug Combinations
  • Liposomes
  • Taxoids
  • gamma-Cyclodextrins
  • Deoxycytidine
  • Docetaxel
  • Caspases
  • gamma-cyclodextrin
  • Gemcitabine
Topics
  • Animals
  • Antineoplastic Agents (administration & dosage, chemistry, therapeutic use)
  • Apoptosis (drug effects)
  • Caspases (metabolism)
  • Cell Cycle (drug effects)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Delayed-Action Preparations (administration & dosage, chemistry, therapeutic use)
  • Deoxycytidine (administration & dosage, analogs & derivatives, chemistry, therapeutic use)
  • Docetaxel
  • Drug Combinations
  • Drug Liberation
  • Humans
  • Liposomes
  • Mice, Nude
  • Nanostructures (administration & dosage, chemistry, therapeutic use)
  • Osteosarcoma (drug therapy, pathology)
  • Taxoids (administration & dosage, chemistry, therapeutic use)
  • Tumor Burden (drug effects)
  • Xenograft Model Antitumor Assays
  • gamma-Cyclodextrins (administration & dosage, chemistry, therapeutic use)
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: